Intron retention is a widespread mechanism of tumor-suppressor inactivation

H Jung, D Lee, J Lee, D Park, YJ Kim, WY Park… - Nature …, 2015 - nature.com
H Jung, D Lee, J Lee, D Park, YJ Kim, WY Park, D Hong, PJ Park, E Lee
Nature genetics, 2015nature.com
A substantial fraction of disease-causing mutations are pathogenic through aberrant
splicing. Although genome profiling studies have identified somatic single-nucleotide
variants (SNVs) in cancer, the extent to which these variants trigger abnormal splicing has
not been systematically examined. Here we analyzed RNA sequencing and exome data
from 1,812 patients with cancer and identified∼ 900 somatic exonic SNVs that disrupt
splicing. At least 163 SNVs, including 31 synonymous ones, were shown to cause intron …
Abstract
A substantial fraction of disease-causing mutations are pathogenic through aberrant splicing. Although genome profiling studies have identified somatic single-nucleotide variants (SNVs) in cancer, the extent to which these variants trigger abnormal splicing has not been systematically examined. Here we analyzed RNA sequencing and exome data from 1,812 patients with cancer and identified ∼900 somatic exonic SNVs that disrupt splicing. At least 163 SNVs, including 31 synonymous ones, were shown to cause intron retention or exon skipping in an allele-specific manner, with ∼70% of the SNVs occurring on the last base of exons. Notably, SNVs causing intron retention were enriched in tumor suppressors, and 97% of these SNVs generated a premature termination codon, leading to loss of function through nonsense-mediated decay or truncated protein. We also characterized the genomic features predictive of such splicing defects. Overall, this work demonstrates that intron retention is a common mechanism of tumor-suppressor inactivation.
nature.com